Objective Prenatal exposure to the antiseizure medication (ASM) valproate is associated
with an increased risk of congenital malformations, but warnings against the use of valproate …

Importance There is concern about neurodevelopmental outcomes associated with prenatal
exposure to valproate and other antiepileptic drugs (AEDs) among children of mothers with …

BACKGROUND: Use of valproate in pregnancy, especially in doses over 1000mg a day, is
known to be associated with a higher risk for major congenital malformations compared with …

Despite extensive research efforts over decades, the teratogenic profile of valproic acid
(VPA) remains obscure. We performed cumulative and conventional meta‐analyses of …

Importance Valproate is an antiepileptic drug (AED) used in the treatment of epilepsy and
many other neurological and psychiatric disorders. Its use in pregnancy is associated with …

Objective–To study the possible dose dependence of the foetal malformation rate after
exposure to sodium valproate in pregnancy Methods–Analysis of records of all foetuses in …

Abstract Information available on the risks of neurodevelopmental disorders (NDs)
associated with in utero exposure to valproate (VPA) and to other antiepileptic drugs (AEDs) …

Background: Use of pregnancy registries is a common method of postmarketing surveillance
of pregnancy outcomes to identify potential teratogens. However, with the increase in …

Importance Use of valproate and certain other antiseizure medications (ASMs) in pregnancy
is associated with abnormal fetal brain development with potential long-term implications for …

Background The use of valproic acid in the first trimester of pregnancy is associated with an
increased risk of spina bifida, but data on the risks of other congenital malformations are …